Lentivirus-mediated transfer of gene encoding fibroblast growth factor-18 inhibits intervertebral disc degeneration

SHENG LU and CHAO-WEI LIN

Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China

Received September 17, 2020; Accepted April 23, 2021

DOI: 10.3892/etm.2021.10288

Abstract. Fibroblast growth factor 18 (FGF-18) is a well-characterized anabolic growth factor involved in cartilage homeostasis. However, the effect of FGF-18 on intervertebral disc (IVD) degeneration has not been investigated. The present study aimed to investigate the role of FGF-18 in the process of rabbit IVD degeneration. In vitro, primary nucleus pulposus cells (NPs) were cultured and transfected with a lentivirus. Tert-butyl hydroperoxide (TBHP) was used to induce apoptosis in NPs on the second passage, while overexpression of FGF-18 in NPs attenuated TBHP-induced apoptosis. A rabbit annular puncture model was generated to induce IVD degeneration in vivo. The discs were injected with an FGF-18-overexpression lentivirus or a negative control lentivirus. In the sham group, the discs were exposed and not punctured. Disc degeneration was evaluated using H&E staining and a histological grading system. Reverse transcription-quantitative PCR was used to detect the expression of the extracellular matrix-degrading enzymes matrix metalloproteinase-3 (MMP-3) and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5). Nucleus pulposus apoptosis was detected via western blotting, immunohistochemical methods and TUNEL staining. Histologic examination showed that disc degeneration was attenuated after FGF-18 overexpression treatment. At 8 weeks after surgery, the expression of MMP-3 and ADAMTS-5 in the annular puncture groups was higher compared with in the sham group. FGF-18 treatment inhibited the expression of MMP-3 and ADAMTS-5 at the mRNA level. Western blot assays indicated that the expression level of Bax was significantly reduced in the FGF-18 groups, and that the expression level of Bcl-2 was significantly increased compared with those in the control group. Moreover, immunohistochemical analysis indicated that the FGF-18 group exhibited a lower percentage of cleaved caspase 3-positive NPs. Quantification of the TUNEL staining demonstrated that the FGF-18 group had fewer apoptotic NPs than the control group. These findings indicated that FGF-18 could delay IVD degeneration by inhibiting the apoptosis of NPs and the expression of matrix-degrading enzymes.

Introduction

Intervertebral disc (IVD) degeneration is the leading cause of chronic back pain, which impairs daily quality of life (1). Until recent developments, conservative treatment or surgical procedures were the only strategies put in place to ameliorate the clinical symptoms, due to poor understanding of the pathophysiology of IVD degeneration (2). The major goals of numerous studies include the development of etiological treatments and the reversal of the degeneration process (3). An increasing number of recent studies have shown that growth factors play important roles in the occurrence and development of IVD degeneration (4-6). Growth factors constitute a group of low molecular weight proteins involved in mitosis and the stimulation of the synthesis of extracellular matrix (1,7). Various growth factors, such as insulin-like growth factor (IGF), TGF-β and bone morphogenetic proteins, have been identified as anabolic regulators that alter homeostasis by shifting the cellular metabolism to the anabolic state in IVD (8-10).

Members of the fibroblast growth factor (FGF) family have been shown to contribute to the regulation of articular and IVD homeostasis (11,12). FGF-18 has been identified as an anabolic growth factor involved in cartilage homeostasis (13). A single intravenous injection of pharmacologic doses of FGF-18 can stimulate the expansion of various cartilage depots in rats, including the rib-sternum junction, trachea, spine and articular cartilage, within 2 weeks (14). In a rat osteoarthritis model, a series of FGF-18 intra-articular injections was able to increase cartilage formation and reduce cartilage degeneration in the tibial plateau (15). However, the role of FGF-18 in IVD degeneration has not been investigated.

IVD degeneration is a chronic process; hence, a single injection may not achieve satisfactory therapeutic effect because the half-life of FGF-18 in the nucleus pulposus is unknown (16). Prolonged exposure to growth factors may be
needed to stimulate biological repair. Gene therapy techniques have been used to explore the effects of growth factors on IVD (17,18). In the present study, a lentivirus-mediated gene transfer approach was used to investigate the effect of FGF-18 treatment on IVD degeneration in a rabbit model. In addition, tert-butyl hydroperoxide (TBHP) was used to induce the apoptosis of nucleus pulposus cells (NPs), and the protective effects of FGF-18 overexpression were evaluated in vitro.

The purpose of the present study was to perform a preliminarily assessment of the application of FGF-18 for the treatment of IVD degeneration. The effects of the lentivirus-mediated delivery of FGF-18 on IVD degeneration were evaluated in a puncture-induced IVD degeneration in vivo model in rabbits and in TBHP-treated NP cells in vitro. The results suggested that FGF-18 can delay IVD degeneration by inhibiting the apoptosis of NPs and the expression of matrix-degrading enzymes.

Materials and methods

Animals. Adult New Zealand 45 female white rabbits (age, 21-23 weeks; weight, 3.0-3.5 kg) were purchased from Experimental Animal Center of Wenzhou Medical University (license no. SYXK(Zhe)2010-0150). All procedures and experimental operations were approved by the Animal Care and Use Committee of Wenzhou Medical University and conformed to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (19).

Reagents and antibodies. TBHP and type II collagenase were obtained from Sigma-Aldrich; Merck KGaA. Rabbit anti-FGF-18 antibody was purchased from LifeSpan Biosciences. Mouse monoclonal anti-Bcl-2 (cat. no. ab6992) and anti-Bax (cat. no. ab3191) antibodies were purchased from Abcam. Mouse monoclonal anti-GAPDH antibody (cat. no. #51332), rabbit monoclonal anti-cleaved caspase-3 antibody (cat. no. #9664), goat anti-rabbit IgG-HRP (cat. no. #7047) and goat anti-mouse IgG-HRP (cat. no. #7076) were purchased from Cell Signaling Technology, Inc. Mouse monoclonal anti-Flag antibody (cat. no. F3165) was purchased from Sigma-Aldrich; Merck KGaA. An in situ cell death detection kit, POD (cat. no. 11684817910) was purchased from Roche Diagnostics.

Lentiviral vector construction and lentivirus production. The rabbit FGF-18 sequence was obtained from the NCBI database (https://www.ncbi.nlm.nih.gov/nuccore/XM_002710377.3). A Ubi-MCS-3FLAG-SV40-EGFP vector (Gv287 backbone; Shanghai GeneChem Co., Ltd.) was linearized using the AgeI restriction enzyme (New England BioLabs, Inc.). To create the recombinant Ubi-LV vector, a fragment containing FGF-18 was constructed into the GV287 vector. Then, the recombinant Ubi-LV vector was transformed into 293T cells [cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.), containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin, and placed at 37°C in a humidified incubator containing 5% CO₂)]. After identification by PCR and sequencing (data not shown), the 20 µg Ubi-LV vector in combination with the lentiviral packaging vectors (15 µg pHelper1.0 and 20 µg pHelper2.0) (Shanghai GeneChem Co., Ltd.) were transfected into 293T cells, using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) to generate the virus. The virus titer was determined using the gradient dilution method (20).

NP culture and viability assay. Rabbits were euthanized with an overdose of 10% sodium pentobarbital (100 mg/kg) via intravenous injection. Death was verified by cessation of the heartbeat and lack of movement. The gel-like nucleus pulposus tissue was separated from the anulus fibrosus under a dissection microscope, and the tissue was treated with 0.1% collagenase and 2 U/ml hyaluronidase for 4 h at 37°C. Subsequently, the digested tissue was transferred as explants cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% heat-inactivated FBS (Gibco; Thermo Fisher Scientific, Inc.) and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) in a humidified atmosphere containing 5% CO₂ at 37°C. The NPs separated from the explant culture after 1 week. Confluent cells were harvested by using 0.25% trypsin-EDTA solution and sub-cultured in 10-cm dishes or 6-well plates. When reaching 20-30% confluence, corresponding to the stage with optimal infection efficiency, the cells at first passage were infected with various concentrations of lentivirus (with MOI ranging from 1-100). Fluorescent protein expression in the cells was observed using an inverted fluorescence microscope (Nikon Corporation) at 24, 48 and 72 h post-infection to assess the infection efficiency. After a second passage, the cells were treated with TBHP at various concentration (0, 50, 100, 200, 300, 500 µM) for 4 h at 37°C. Then, cell viability was determined by Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.) at 37°C for 2 h, according to the manufacturer's instructions.

Animal model and lentivirus-mediated gene transfer. A rabbit annular puncture model (5 rabbits/group) was generated to induce IVD degeneration at L3/4, L4/5 and L5/6 (21). All animals were anesthetized intraperitoneally with 2% (w/v) pentobarbital (40 mg/kg). After puncture, ~10⁸ PFU of the FGF-18-overexpression lentivirus were injected into the center of the rabbit nucleus pulposus using a 100-µl micro-syringe (Hamilton Company) along the initial foramina. Negative control lentivirus with no gene overexpression was injected in the control group. In the sham group, IVDs were only exposed and were not punctured.

Histologic and immunohistochemical analysis. At 8 weeks after surgery, the rabbits were sacrificed via an intravenous injection of 10% sodium pentobarbital (100 mg/kg). The IVDs were separated, fixed in 10% neutral buffered formalin at 4°C for 3 days and decalcified in the presence of 10% EDTA for 2-6 weeks. The samples were incubated in a mixture of xylene and paraffin at 25°C for 15 min, and paraffin I and paraffin II were then added for 50-60 min each. The tissue was subsequently sliced into 5-µm-thick sections. For H&E staining, the sections were washed three times with PBS for 5 min each. Then, the sections were dehydrated in 95% alcohol, permeabilized with xylene and mounted with
neutral resin. A widely used grading scale was subsequently used to assess the anulus fibrosus, the border between the anulus fibrosus and nucleus pulposus, the cellularity of the nucleus purpose and the matrix of the nucleus pulposus (14). Grades ranged from 4 to 12, where ‘normal’ is 1 point for each of the four categories listed above, for a total of four points (grade 4). Since there is a maximum of three points for each parameter, a total of 12 points (grade 12) is representative of severe degeneration (20). A grading system was used to evaluate semi-quantitatively disc degeneration as previously described (22).

Immunohistochemical staining for cleaved caspase-3 was performed using the sections obtained 8 weeks after the operation. After incubation with 3% H₂O₂, at room temperature for 10 min, the tissue was washed with PBS, boiled in 0.1% trisodium citrate at 90°C for 15 min for antigen retrieval and blocked with BSA (cat. no. 4240GR100; NeoFroxx GmbH) at room temperature for 1 h. Subsequently, the sections were incubated with a rabbit anti-cleaved caspase-3 monoclonal antibody (1:200) diluted in PBS overnight at 4°C, followed by an incubation with HRP-conjugated secondary antibodies (1:1,000) for 1 h at room temperature. The staining was visualized with 3,3'-diaminobenzidine (OriGene Technologies, Inc.), and the sections were counterstained with hematoxylin at room temperature for 1 min, dehydrated with graded ethanol, clarified with dimethylbenzene and sealed with neutral resin. A widely used grading scale was subsequently used to assess the anulus fibrosus, the border between the anulus fibrosus and nucleus pulposus, the cellularity of the nucleus purpose and the matrix of the nucleus pulposus (14). Grades ranged from 4 to 12, where ‘normal’ is 1 point for each of the four categories listed above, for a total of four points (grade 4). Since there is a maximum of three points for each parameter, a total of 12 points (grade 12) is representative of severe degeneration (20). A grading system was used to evaluate semi-quantitatively disc degeneration as previously described (22).

Reverse transcription-quantitative PCR (RT-qPCR) analysis. Total RNA was extracted from the nucleus pulposus using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and then RNA was reversely transcribed into cDNA with a SuperScript™ One-Step Reverse Transcription kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. The mRNA expression of matrix metalloproteinase-3 (MMP-3) and A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS-5) were quantified using the iTaq™ Universal SYBR-Green Supermix (Bio-Rad Laboratories, Inc.) on the Real-Time PCR detection System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions used were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 60°C for 30 sec and 72°C for 30 sec. Samples were amplified independently at least three times. Relative gene expression was converted using the 2^ΔΔCq method against GAPDH (23). All primer sequences were designed and synthesized by Sangon Biotech Co. Ltd. and are presented in Table I.

Western blot analysis. The nucleus pulposus tissues or cultured cells were lysed in ice-cold RIPA buffer (cat. no. P0013B; Beyotime Institute of Biotechnology), 100 mM Na₂VO₄, 100 mM NaF, 100 mM PMSF (cat. no. ST506; Beyotime Institute of Biotechnology) at 4°C for 30 min, then centrifuged at 12,000 x g for 30 min at 4°C, and protein concentration was determined using the BCA method (Pierce BCA Protein Assay kit; Thermo Fisher Scientific, Inc.). Finally, lysates were mixed with 5X loading buffer (cat. no. P1040; Beijing Solarbio Science & Technology Co., Ltd.) and boiled at 100°C for 10 min. The equivalent of 20 μg of protein was separated via 12% SDS-PAGE and then transferred onto a PVDF membrane (MilliporeSigma). The membranes were blocked with 5% non-fat milk at room temperature for 1 h and then incubated overnight at 4°C with anti-Flag (1:800), anti-Bcl-2 (1:1,000), anti-Bax (1:1,000) and anti-GAPDH (1:1,000) antibodies. After the membranes were washed with TBS-Tween-20 (0.1%), HRP-conjugated antibodies (1:5,000) was added to develop the signal at room temperature for 1.5 h. Immunoreactive proteins were visualized using an ECL detection kit (Bio-Rad Laboratories, Inc.) and blots were analyzed using Quantity One software v4.6.2 (Bio-Rad Laboratories, Inc.).

Table I. Primer sequences used for reverse transcription-quantitative PCR.

| Gene   | Primer         | Sequence                           | Size, bp |
|--------|----------------|------------------------------------|----------|
| MMP3   | Forward        | 5'-CCCAAAAGTGACAAAAACTCA-3'        | 118      |
|        | Reverse        | 5'-AGTCCACCTCTCCAGACC-3'          |          |
| ADAMTS-5 | Forward      | 5'-GTTGAGATGCGAGAGAGAC-3'         | 139      |
|        | Reverse        | 5'-TCTTTGCGTAAAAGCTTG-3'          |          |
| GAPDH  | Forward        | 5'-GAAACGGGAAACTCAG-3'            | 117      |
|        | Reverse        | 5'-TCACCACTTTTGTAGTG-3'           |          |

MMP-3, matrix metalloproteinase-3; ADAMTS-5, A disintegrin and metalloproteinase with thrombospondin motifs 5.
Statistical analysis. The results are presented as the mean ± SD unless specified otherwise. All experiments were repeated at least three times. Statistical significance was evaluated by using Student's t-test, or comparison between multiple groups was assessed using one-way ANOVA followed by Tukey's post hoc test. For histological grades, data are expressed as a median (interquartile range) and the Kruskal-Wallis test with Dunn's post hoc test was applied to compare multiple groups. SPSS 22.0 (IBM Corp.) and GraphPad Prism 7.0 software (GraphPad Software, Inc.) were used to perform analyses. P<0.05 was considered to indicate a statistically significant difference.

Results

Overexpression of FGF-18 inhibits apoptosis in NPs in vitro. Pre-confluent NPs (Fig. 1A) were transfected with various concentrations of lentivirus (with MOI ranging from 1-100). Cells in green indicated successful transfection (Fig. 1C). CCK-8 assay results indicated that lentiviral transfection at concentrations ≤20 MOI improved cell viability after 72 h (Fig. 1D). However, cell viability was decreased by TBHP treatment in a dose-dependent manner (Fig. 1B). The transfection efficiency in vitro was confirmed with quantification of FGF-18 expression in NPs via western blotting (Fig. 1E and F).

FGF-18 overexpression significantly protected NPs against TBHP-induced cell death (Fig. 2A). The expression levels of Bax and Bcl-2 were detected using western blot analyses (Fig. 2B). The results indicated that 100 µM TBHP markedly increased the expression of an apoptosis-related protein (Bax) and decreased the expression of an anti-apoptotic protein (Bcl-2), whereas overexpression of FGF-18 inhibited TBHP-induced apoptosis (Fig. 2C and D).

Anti-catabolic and anti-apoptotic effects of FGF-18 on NPs in vivo. To evaluate the transfection efficiency of FGF-18 overexpression lentivirus in NPs, western blot analysis of exogenous Flag protein was performed. The Flag protein was designed to be co-expressed with FGF-18 and was not expressed in non-infected NPs. As presented in Fig. 3A, the protein level of Flag in rabbit NPs was increased 8 weeks after they were transfected with FGF-18 overexpression lentivirus, whereas it was not detected in the sham or control group.
RT-qPCR results demonstrated that the mRNA levels of the pro-catabolic indicators MMP-3 and ADAMTS-5 in the control group were markedly increased compared with the sham group (Fig. 3B). FGF-18 treatment decreased the expression levels of both MMP-3 and ADAMTS-5 at the mRNA level compared with the control group (Fig. 3B). As indicated by western blot analysis, FGF-18 treatment also inhibited the expression levels of both MMP-3 and ADAMTS-5 at the protein level compared with the control group (Fig. 3C). These results suggest that FGF-18 has a protective effect on NP cells in vivo.
analysis, the expression levels of Bax in the FGF-18 group were significantly reduced compared with those in the control group, and the expression level of Bcl-2 was increased in the FGF-18 group compared with the control group (Fig. 3C and D).

Histologic examination of the rabbit discs after transfer of the FGF-18 overexpression lentivirus. H&E-stained IVDs were observed 8 weeks after the operation (Fig. 4). Abnormalities, such as inflammation or cancerous growth, were not detected in any of the groups. However, after 8 weeks, NPs of the control group had collapsed. As illustrated in Fig. 4B, the destruction structure was accompanied by the absence of vacuoles and fewer NPs, and the space was filled with a hypocellular fibrocartilaginous matrix. By contrast, the rabbits treated with the FGF-18 overexpression lentivirus exhibited numerous large vacuolated cells and smaller chondrocyte-like cells, and the structure was more complete as observed in Fig. 4C. The histological grades in the control group were significantly higher compared with in the sham group (Fig. 4D), and they were significantly lower in the FGF-18 group compared with in the control group (Fig. 4D).

Immunohistochemical analysis of cleaved caspase-3 in rabbit NPs. Immunohistochemical analysis of the in vivo experiment indicated that the number of cleaved caspase-3-positive NPs (brown positive signal) was decreased in the sham group. The expression of cleaved caspase-3 in the control group was significantly increased 8 weeks after surgery (Fig. 5A and B). However, the percentage of cleaved caspase-3-positive cells in the FGF-18 group was reduced compared with that in the control group (Fig. 5C).

FGF-18 reduces the NP apoptosis rate. TUNEL staining was performed to analyze the NP apoptosis rate. The apoptosis rate of NPs was increased over time in the control and FGF-18 groups. However, the apoptosis rate was decreased for the FGF-18 group (Fig. 6A). Quantification of TUNEL staining showed that the FGF-18 group exhibited significantly fewer apoptotic NPs compared with the control group (Fig. 6B).

Discussion

The present study suggested that FGF-18 overexpression can delay the process of IVD degeneration. FGF-18 was involved in the protection of NPs against apoptosis, and may suppress extracellular matrix degeneration and promote extracellular matrix synthesis. The results of the in vivo experiments indicated that FGF-18 may ameliorate the process of IVD degeneration in a puncture-induced rabbit model. However, the exact mechanism via which FGF-18 attenuates the apoptosis of NPs remains unclear. Further research will be performed to determine the detailed mechanism.

Previous studies have indicated that biological treatments can be used to stimulate cell activity, increase the synthesis of extracellular matrix and reverse the process of IVD degeneration (24). For instance, injection of bone morphogenetic protein-7 into IVDs induced an increase in the height of IVDs (22). In addition, Nishida et al (25) reported that the injection of an adenovirus construct encoding TGF-β into lumbar discs may induce proteoglycan (PG) synthesis in rabbits. Interestingly, the gene transfer of tissue inhibitor of metalloproteinases 1, an inhibitor of catabolic enzymes, also increased the PG content in the pellet cultures of human
Figure 5. Immunostaining of cleaved caspase-3 in nucleus pulposus cells. Staining in (A) sham, (B) control and (C) FGF-18 groups at 8 weeks after the operation. Scale bar =20 µm. (D) Quantification of cleaved caspase-3-positive cells (n=5). Data are presented as the mean ± SD. **P<0.01 vs. sham; *P<0.05 vs. control. FGF-18, fibroblast growth factor 18.

Figure 6. Detection of apoptosis in nucleus pulposus. (A) TUNEL staining for apoptotic cells (green). The nuclei are labelled with DAPI (blue). Scale bar=20 µm. (B) Quantification of the nucleus pulposus cell apoptosis rate (n=5). Data are presented as the mean ± SD. **P<0.01 vs. sham group; ##P<0.01 vs. control group. FGF-18, fibroblast growth factor 18.
IVD cells (26). FGF-18 has been identified as a powerful anabolic growth factor involved in cartilage homeostasis (27). The present study hypothesized that FGF-18 can protect against IVD degeneration, which was investigated using a lentivirus-mediated gene transfer approach in a rabbit annular needle puncture model.

In the NP in vitro model, overexpression of FGF-18 increased cell viability and inhibited the apoptosis induced by TBHP. To study the effect of FGF-18 in vivo, the transfection efficiency of FGF-18 overexpression lentivirus was first assessed by measuring the expression of Flag protein co-expressed with FGF-18. The data indicated that Flag was stably expressed 8 weeks after the operation. Histological examination indicated that local injection of FGF-18 overexpression lentivirus into the discs delayed the process of degeneration. In normal IVDs, anabolic factors promote the generation of PG and collagen, and catabolic factors inhibit the synthesis of the matrix to maintain a dynamic balance (28). A previous study reported that extracellular matrix degradation enzymes, such as MMPs and ADAMTSs, which are upregulated by proinflammatory cytokines, are characteristics of IVD degeneration (29). RT-qPCR was used to detect the expression of the catabolic indicators MMP-3 and ADAMTS-5 and demonstrated that their mRNA levels were increased in the control group. The expression level was decreased after FGF-18 intervention, suggesting that FGF-18 has an inhibitory effect on the synthesis of extracellular matrix degradation enzymes in IVD.

The apoptosis of NPs may play critical pathogenic roles in IVD degradation (30‑32). A previous study showed that Bcl-2 overexpression in NPs prevented apoptotic cell death under serum-starved conditions (33). Importantly, another previous study reported that caspase-3 small interfering RNA attenuated Bcl-2 expression induced in rabbit IVD degeneration (34). These results indicate that inhibition of apoptosis of disc NPs may mitigate disc degeneration. Thus, in the present study, several apoptotic markers were quantified to evaluate the function of FGF-18 in NPs. The results of the western blot analysis indicated that the expression level of Bax was significantly reduced in the FGF-18 groups compared with in the control group. The expression level was decreased after FGF-18 treatment. Thus, apoptotic cell death of NPs was rescued by FGF-18 therapy in the present rabbit model of IVD degeneration.

The purpose of the present study was to preliminarily explore possible effects of the application of FGF-18 for the treatment of IVD degeneration. Using in situ hybridization technique, Ellsworth et al (14) found that FGF receptor (FGFR), FGFR3IIIC and FGFR2IIIC mRNAs were localized in chondrocytes of human articular cartilage, suggesting a potential role of FGFR2 or FGFR3 in FGF-18-mediated human articular cartilage homeostasis. In addition, FGF3 can activate MAPK signaling pathways, with various downstream signaling cascades specific to the subtypes activated by FGFR (35). FGFR1-mediated MAPK activation leads to the activation of runt-related transcription factor 2 and ETS like-1 protein, and subsequently induces the expression of multiple MMPs, aggrecanases and leads to chondrocyte hypertrophy (36). FGFR3-mediated MAPK signaling could activate a different set of the downstream transcription factors, leading to chondroprotective effects (37). To date, the precise signaling pathway mediated by the FGFR3-FGF-18 axis in cartilage homeostasis is unknown. Thus, each part of the molecular mechanism requires investigation in vivo and in vitro. A comparison of the expression of extracellular matrix-degrading enzymes MMP-3 and ADAMTS-5 indicated that FGF-18 had anti-catabolic effects in IVD degeneration. Furthermore, the present data of the immunohistochemical analysis and TUNEL assay indicated that the protective effects were associated with inhibition of apoptosis in NPs.

In conclusion, the present study indicated that TBHP-induced apoptosis can be attenuated in FGF-18-treated NPs, and FGF-18 treatment can ameliorate puncture-induced IVD degeneration in rabbits. These findings suggested that a therapeutic strategy of FGF-18 application may be a promising treatment for IVD degeneration.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Science-technology Program of Wenzhou Municipal Sci-Tech Bureau (grant no. 2020Y1553).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SL and CL searched the literature, designed the experiments and performed the experiments. SL analyzed, interpreted the data and wrote the manuscript. CL revised the manuscript. SL and CL confirmed the authenticity of all the raw data. Both authors have read and approved the final manuscript.

Ethics approval and consent to participate
All procedures and experimental operations were approved by the Animal Care and Use Committee of Wenzhou Medical University.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Masuda K and An HS: Growth factors and the intervertebral disc. Spine J 4 (Suppl 6): S330–S340, 2004.
2. Kamali A, Ziadlou R, Lang G, Pfannkuche J, Cui S, Li Z, Richards RG, Alini M and Grad S: Small molecule-based treatment approaches for intervertebral disc degeneration: Current options and future directions. Theranostics 11: 27-47, 2021.

3. Cazzanelli P and Wurzt-Kovak K: MicroRNAs in intervertebral disc degeneration, apoptosis, inflammation, and mechanobiology. Int J Mol Sci 21: 3601, 2020.

4. Kim MJ, Lee JH, Kim JS, Kim HY, Lee HC, Byun JH, Lee JH, Kim NH and Oh SH: Intervertebral disc regeneration using stem cell/growth factor-loaded porous particles with a leaf-stacked structure. Biomacromolecules 21: 4795-4805, 2020.

5. Cui H, Zhang J, Li Z, Chen F, Cui H, Du X, Liu H, Wang J, Diwan AD and Zheng Z: Growth differentiation factor-6 attenuates inflammatory and pain-related factors and degenerated disc-induced pain behaviors in rat model. J Orthop Res 39: 959-970, 2021.

6. Hodgkinson T, Shen B, Diwan A, Hoyland JA and Richardson SM: Therapeutic potential of growth differentiation factors in the treatment of degenerative disc diseases. JOR Spine 2: e1045, 2019.

7. Clouet J, Fusellier M, Camus A, Le Visage C and Guicheux J: Intervertebral disc regeneration: From cell therapy to the development of novel bioinspired endogenous repair strategies. Adv Drug Deliv Rev 146: 306-324, 2019.

8. An JL, Zhang W, Zhang J, Lian LC, Shen Y and Ding WY: Vitamin D improves the efficacy of TGF-β and IGF-1 in intervertebral disc of diabetic rats. Exp Biol Med (Maywood) 242: 1254-1261, 2017.

9. Chen S, Liu S, Ma K, Zhao L, Lin H and Shao Z: TGF-β signaling in inter-vertebral disc health and disease. Osteoarthritis Cartilage 27: 1109-1117, 2019.

10. Xu Z, Zhai X, Zinkle A, Chen L and Mohammadi M: Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Nat Rev Rheumatol 16: 547-564, 2020.

11. Adams MA and Roughley PJ: What is intervertebral disc degeneration, and what causes it? Spine (Phila Pa 1976) 31: 215-216, 2006.

12. Clouet J, Fusellier M, Camus A, Le Visage C and Guicheux J: Intervertebral disc regeneration: From cell therapy to the development of novel bioinspired endogenous repair strategies. Adv Drug Deliv Rev 146: 306-324, 2019.

13. An JL, Zhang W, Zhang J, Lian LC, Shen Y and Ding WY: Vitamin D improves the efficacy of TGF-β and IGF-1 in intervertebral disc of diabetic rats. Exp Biol Med (Maywood) 242: 1254-1261, 2017.

14. Chen S, Liu S, Ma K, Zhao L, Lin H and Shao Z: TGF-β signaling in inter-vertebral disc health and disease. Osteoarthritis Cartilage 27: 1109-1117, 2019.

15. Xu Z, Zhai X, Zinkle A, Chen L and Mohammadi M: Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Nat Rev Rheumatol 16: 547-564, 2020.

16. Adams MA and Roughley PJ: What is intervertebral disc degeneration, and what causes it? Spine (Phila Pa 1976) 31: 215-216, 2006.

17. Clouet J, Fusellier M, Camus A, Le Visage C and Guicheux J: Intervertebral disc regeneration: From cell therapy to the development of novel bioinspired endogenous repair strategies. Adv Drug Deliv Rev 146: 306-324, 2019.

18. An JL, Zhang W, Zhang J, Lian LC, Shen Y and Ding WY: Vitamin D improves the efficacy of TGF-β and IGF-1 in intervertebral disc of diabetic rats. Exp Biol Med (Maywood) 242: 1254-1261, 2017.

19. Chen S, Liu S, Ma K, Zhao L, Lin H and Shao Z: TGF-β signaling in inter-vertebral disc health and disease. Osteoarthritis Cartilage 27: 1109-1117, 2019.

20. Xu Z, Zhai X, Zinkle A, Chen L and Mohammadi M: Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Nat Rev Rheumatol 16: 547-564, 2020.

21. Adams MA and Roughley PJ: What is intervertebral disc degeneration, and what causes it? Spine (Phila Pa 1976) 31: 215-216, 2006.

22. Clouet J, Fusellier M, Camus A, Le Visage C and Guicheux J: Intervertebral disc regeneration: From cell therapy to the development of novel bioinspired endogenous repair strategies. Adv Drug Deliv Rev 146: 306-324, 2019.

23. An JL, Zhang W, Zhang J, Lian LC, Shen Y and Ding WY: Vitamin D improves the efficacy of TGF-β and IGF-1 in intervertebral disc of diabetic rats. Exp Biol Med (Maywood) 242: 1254-1261, 2017.

24. Chen S, Liu S, Ma K, Zhao L, Lin H and Shao Z: TGF-β signaling in inter-vertebral disc health and disease. Osteoarthritis Cartilage 27: 1109-1117, 2019.

25. Xu Z, Zhai X, Zinkle A, Chen L and Mohammadi M: Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Nat Rev Rheumatol 16: 547-564, 2020.

26. Adams MA and Roughley PJ: What is intervertebral disc degeneration, and what causes it? Spine (Phila Pa 1976) 31: 215-216, 2006.